ArticlePloS one2019
Anti-Candida albicans effect of the protein-carbohydrate fraction obtained from the coelomic fluid of earthworm Dendrobaena veneta.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Earthworm Coelomocytes and Coelomic Fluid: Innate Immunity, Toxicological Responses, and Research Applications.Animals : an open access journal from MDPI · 2026Review
- Anti-Candida albicans effect of the new antifungal compound Venetin-1 obtained from earthworms versus amphotericin B.Scientific reports · 2026Article
- Investigating the in-vitro and in-vivo potential of Eudrilus eugeniae coelomic fluid fractions on cancer cell lines: insights into mechanisms and therapeutic implications.Medical oncology (Northwood, London, England) · 2025Article
- Morphological and environmental analysis of the glacier ice alga Ancylonema alaskanum.Scientific reports · 2025Article
- Tailocin-Mediated Interactions Among Soft Rot Pectobacteriaceae.Molecular ecology · 2025Article
- Animal origins free products in cell culture media: a new frontier.Cytotechnology · 2025Review
- Identification of lysozyme in Venetin-1 nanoparticle from the coelomic fluid of the earthwormFrontiers in molecular biosciences · 2025Article
- Unveiling resilience: coelomic fluid bacteria's impact on plant metabolism and abiotic stress tolerance.Plant signaling & behavior · 2024Article
- Preliminary proteomic analysis of mouse lung tissue treated with cyclophosphamide and Venetin-1.Scientific reports · 2024Article
- Pharmacological effects of bioactive agents in earthworm extract: A comprehensive review.Animal models and experimental medicine · 2024Review
- Prospects of earthworm coelomic fluid as a potential therapeutic agent to treat cancer.Cancer metastasis reviews · 2024Review
- Autophagy of Candida albicans cells after the action of earthworm Venetin-1 nanoparticle with protease inhibitor activity.Scientific reports · 2023Article
- Atypical changes in Candida albicans cells treated with the Venetin-1 complex from earthworm coelomic fluid.Scientific reports · 2023Article
- Novel Venetin-1 nanoparticle from earthworm coelomic fluid as a promising agent for the treatment of non-small cell lung cancer.Scientific reports · 2022Article
- Cinnamon Leaf and Clove Essential Oils Are Potent Inhibitors ofMicroorganisms · 2022Article
- Metabolic, structural, and proteomic changes in Candida albicans cells induced by the protein-carbohydrate fraction of Dendrobaena veneta coelomic fluid.Scientific reports · 2021Article
- Review
- Morphological and physicochemical diversity of snow algae from Alaska.Scientific reports · 2020Article
- Candida albicans cell wall as a target of action for the protein-carbohydrate fraction from coelomic fluid of Dendrobaena veneta.Scientific reports · 2020Article
- Anticancer Activity of Earthworm Powder (Lumbricus terrestris) Against MCF-7 and PC-3 Cancer Cell Lines.Journal of gastrointestinal cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An antifungal active fraction (AAF) from the coelomic fluid (CF) of the earthworm Dendrobaena veneta was isolated. The aim of the study was to analyze the antifungal activity of the AAF and to carry out chemical characterization of the fraction. The active fraction showed antifungal activity against a clinical C. albicans isolate, C. albicans ATCC 10231, and C. krusei ATCC 6258. It effectively reduced the metabolic activity of C. albicans cells and influenced their morphology after 48 hours of incubation. Scanning electron microscopy (SEM) images revealed loss of integrity of the cell wall induced by the active fraction. Calcofluor White staining showed changes in the structure of the C. albicans cell wall induced by the AAF. The fungal cells died via apoptosis and necrosis after the treatment with the studied fraction. Electrophoresis under native conditions revealed the presence of two compounds in the AAF, while SDS/PAGE gel electrophoresis showed several protein and carbohydrate compounds. The active fraction was analyzed using Raman spectroscopy, MALDI TOF/TOF, and ESI LC-MS. The Raman analysis confirmed the presence of proteins and determined their secondary structure. The MALDI TOF/TOF analysis facilitated detection of four main compounds with a mass of 7694.9 m/z, 12292.3 m/z, 21628.3 m/z, and 42923.2 m/z in the analyzed fraction. The presence of carbohydrate compounds in the preparation was confirmed by nuclear magnetic resonance (NMR) and gas chromatography (GC-MS). The ATR-FTIR spectrum of the AAF exhibited high similarity to the spectrum of egg white lysozyme. The AAF showed no endotoxicity and cytotoxicity towards normal skin fibroblasts (HSF); therefore, it can be used for the treatment of skin and mucous membrane candidiasis in the future. Given its efficient and selective action, the fraction seems to be a promising preparation with antifungal activity against C. albicans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.